PDA patients with wild type p53 could be treated with 2-Deoxy-D-Glucose (2-DG) by suppressing glycolytic activity to decrease GEM resistance-related genes and an increased apoptosis rate [39]. Here, TP53 is linked to Patent ductus arteriosus.